Biophytis Grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million
Biophytis Grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million
- Biophytis to receive upfront and milestones payments for a total amount up to €108 million, as well as double-digit royaltieson future sales of the product
- Agreement covers commercialization of BIO101 in Latin America
- Biophytis and Blanver intend to collaborate on manufacturing and joint clinical development for Latin America
- Biophytis將獲得高達1.08億歐元的預付款和分階段付款,以及未來產品銷售的兩位數特許權使用費。
- 協議涵蓋了在拉丁美洲商業化BIO101的內容。
- Biophytis和Blanver打算合作製造並聯合開發拉丁美洲的臨床試驗。
PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / June 20, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today announces the signature of an exclusive license agreement with Blanver, one of the leading and most trusted pharmaceutical company in Brazil, for BIO101 (20-Hydroxyecdysone) in Latin American including, but not limited to Brazil, Mexico, Argentina and Colombia.
2024年6月20日,法國巴黎和美國馬薩諸塞州劍橋 / ACCESSWIRE / 臨床階段生物技術公司Biophytis SA(Euronext Growth Paris:ALBPS)(“Biophytis”或“公司”)宣佈已經與巴西領先且最值得信賴的製藥公司之一Blanver簽訂了BIO101(20-羥基蛻皮激素)在包括但不限於巴西,墨西哥,阿根廷和哥倫比亞在內的拉美地區的專屬許可協議。
The agreement provides that Blanver will be responsible for the registration, marketing and commercialization of BIO 101 (20-Hydroxyecdysone) in its various indications: obesity, respiratory infections due to Covid-19, sarcopenia and Duchenne Muscular Dystrophy (DMD) - once Biophytis has successfully completed the planned clinical development programmes for its drug candidate. With 40 years of history, Blanver has become an expert in infectious diseases, osteoporosis and metabolic disorders, which is a perfect match with Biophytis. In addition of Brazil, Blanver has an extensive network of unique distributors that covers the whole Latin America region.
協議規定,一旦Biophytis成功完成其藥物候選的計劃臨床開發項目,Blanver將負責BIO 101(20-Hydroxyecdysone)在其各種適應症(包括肥胖症,由Covid-19引起的呼吸系統感染,肌無力症和杜興肌肉萎縮症)的註冊,營銷和商業化。擁有40年曆史的Blanver已成爲傳染病,骨質疏鬆症和代謝性疾病的專家,這與Biophytis非常相配。除了巴西,Blanver還擁有一個廣泛的獨特分銷網絡,覆蓋整個拉丁美洲地域板塊。
Under the terms of this partnership, Biophytis will be able to receive up to €108 million including an upfront payment and further additional payments if certain objectives are achieved. Biophytis is also eligible to receive double-digit royalties on net sales of BIO101 (20-Hydroxyecdysone) generated in the collaboration territory, after obtaining future marketing authorisations.
根據這項合作協議,Biophytis將能夠最多獲得1.08億歐元的資金,其中包括預付款和實現某些目標後的進一步附加支付。當BIO101(20-羥基蛻皮激素)在合作地區獲得未來的營銷授權後,Biophytis還有資格獲得淨銷售額的兩位數特許權使用費。
This collaboration in one of the main pharma regions in the world, underscores the potential of BIO101 (20-Hydroxyecdysone) which is based on the positive clinical results already obtained in several indications.
這在世界主要的製藥地區之一的合作反映了BIO101(20-羥基蛻皮激素)的潛力,該潛力基於已經在多種適應症中獲得的積極臨床結果。
Stanislas Veillet, CEO of Biophytis, stated: "I warmly welcome this new partnership which is a key milestone that will enable Biophytis to further deploy its strategic roadmap, especially in obesity. This is a unique opportunity for both companies and comes at a crucial time as Brazil is the most fast-growing pharmaceutical market, representing more than $23 billion in 2023. In the LATAM region, 100 million of patients are suffering from obesity. We look forward to continuing our clinical and regulatory development work with Blanver over the coming months and to exploring with them early market access opportunities for our most advanced indications. Together, we aim to deliver solutions to patients and physicians over the years ahead."
Biophytis的首席執行官Stanislas Veillet表示:“我熱烈歡迎這一新夥伴關係,這是一個關鍵的里程碑,將使Biophytis能夠進一步部署其戰略路線圖,特別是在肥胖症領域。這是對雙方公司的獨特機遇,是巴西最快增長的製藥市場,2023年代表超過230億美元。在LATAM地區,有1億患者患有肥胖症。我們期待與Blanver繼續在未來幾個月內進行臨床和監管開發工作,並與他們一起探索最先進適應症的早期市場接觸機會。我們共同致力於在未來幾年向患者和醫生提供解決方案。”
Sergio Frangioni, CEO of Blanver, commented: "Innovation is part of the Blanver DNA, and we are thrilled to partner with Biophytis, to bring this unique medicine in Latin America. We are very confident that the clinical study of the novel BIO101 (20-hydroxyecdysone), will show encouraging results, which will support the medical community to obesity, their effects and bring health and quality of life to so many patients who suffer from this condition."
Blanver的首席執行官Sergio Frangioni評論道:“創新是Blanver DNA的一部分,我們很高興與Biophytis合作,在拉丁美洲引入這種獨特的藥物。我們非常有信心,新穎的BIO101(20-羥基蛻皮激素)的臨床研究將顯示出令人鼓舞的結果,這將支持醫學界對肥胖症及其影響的認識,併爲患有這種病症的患者帶來健康和更高的生活質量。”
****
****
About BIOPHYTIS
關於Biophytis
Biophytis SA is a clinical-stage biotechnology company specializing in the development of drug candidates for age-related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular (sarcopenia, phase 3 ready and Duchenne muscular dystrophy), respiratory (Covid-19 phase 2-3 completed) and metabolic diseases (obesity, phase 2 to be started). The company is based in Paris, France, and Cambridge, Massachusetts. The Company's ordinary shares are listed on Euronext Growth (Ticker: ALBPS -ISIN: FR0012816825). For more information, visit
Biophytis SA是一家專注於開發針對老年疾病的藥物候選品的臨床階段生物技術公司。 BIO101(20-羥基蛻皮激素)是我們主要的藥物候選品,是一種小分子化合物,正在開發肌肉疾病(骨肌萎縮,第3階段準備就緒和杜氏肌萎縮症),呼吸系統疾病(完成Covid-19第2-3階段)和代謝性疾病(肥胖症,第2階段將開始)。該公司總部位於法國巴黎和馬薩諸塞州劍橋。其普通股在歐洲增長公司(股票代碼:ALBPS-ISIN:FR0012816825)上市。有關更多信息,請訪問
About BLANVER
Blanver是一家備受信任的製藥公司之一。
Blanver Farmoquímica e Farmacêutica S.A. is a Brazilian company, founded in 1984, focused on R&D, manufacture and sale of innovative medicines and active pharmaceutical ingredients (APIs). The company plays in the segments of HIV, Hepatitis, Oncology, Hematology and Rare Disease, providing high quality products for expanding the population's access to medicines through partnerships with the Ministry of Health and official laboratories. Blanver is committed in always looking for innovations that will improve people's health and quality of life.
Blanver Farmoquímicae FarmacêuticaSA是一家巴西公司,成立於1984年,專注於研發,製造和銷售創新藥品和活性藥物成分(API)。該公司涉足HIV,肝炎,腫瘤學,血液學和罕見疾病領域,通過與衛生部和官方實驗室的合作,提供高質量的產品,以擴大人民群衆進入藥品的範圍。 Blanver致力於尋找將改善人們健康和生活質量的創新方法。
Forward-looking statements
前瞻性聲明 本新聞稿中包括的關於未來表現和結果、預期、規劃、策略、重點、承諾和其他聲明(包括與我們社會、環境和其他可持續性目標有關的聲明)的非歷史事實的前瞻性聲明,是根據美國聯邦證券法的定義而作出的前瞻性聲明。本新聞稿中關於我們環境和其他可持續性計劃和目標的前瞻性聲明以及其他聲明並不意味着這些聲明對於投資者、我們的業務、運營結果、財務狀況、前景或策略、對我們在可持續發展事項上的影響或其他當事方來說均是重要的,或者必須披露在我們向證券交易委員會(“SEC”)或其他監管機構的備案中。此外,歷史、現有及未來涉及社會、環境和可持續性的相關聲明可能是基於仍在發展的衡量進展的標準、不斷演變的內部控制和流程以及假設,在將來可能會發生變化。前瞻性聲明基於當前的信仰、期望和假設,並受到可能導致實際結果與前瞻性聲明有實質性差異的重大風險、不確定性和情況變化的影響。
This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook,""believes,""expects,""potential,""continues,""may,""will,""should,""could,""seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of thesewords or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable.However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face» section from the Company's 2023 Financial Report available on BIOPHYTIS website () and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.
本新聞稿包含前瞻性聲明。前瞻性聲明包括所有非歷史事實陳述。在某些情況下,您可以通過使用諸如“展望”,“相信”,“期望”,“潛力”,“繼續”,“可能”,“將”或這些單詞的負面版本或其他可比較的單詞來識別這些前瞻性聲明。此類前瞻性聲明是基於Biophytis認爲合理的假設。但是,無法保證這些前瞻性聲明中所包含的聲明將得到驗證,這些聲明還受到各種風險和不確定性的影響。本新聞稿中包含的前瞻性聲明也會受到Biophytis尚未知曉或目前不被Biophytis認爲具有重要性的風險的影響。因此,將存在或將存在重要因素,可能導致實際結果或結果與這些聲明所示的結果有所不同。另請參閱Biophytis網站()上公佈的公司2023年財務報告中的“公司將面臨的風險和不確定性”部分,以及20-F表中“風險因素”部分以及提交給SEC(美國證券交易委員會)的其他表格。我們不承擔公開更新或審查任何前瞻性聲明的義務,無論是因爲新信息,未來發展還是其他方面,除非法律要求。
Biophytis contacts
Biophytis聯繫方式
Investor relations
Nicolas Fellmann, CFO
Investors@biophytis.com
投資者關係
Nicolas Fellmann,CFO
Investors@biophytis.com
Pharma partners
Edouard Bieth, CBO
edouard.bieth@biophytis.com
製藥合作伙伴
埃杜爾·畢厄,首席商務官
edouard.bieth@biophytis.com
Media
媒體
Antoine Denry:antoine.denry@taddeo.fr- +33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr - +33 6 38 31 90 50
Antoine Denry:antoine.denry@taddeo.fr- +33 6 18 07 83 27
Nizar Berrada: nizar.berrada@taddeo.fr - +33 6 38 31 90 50
Blanver contacts
Blanver聯繫方式
Investor relations
Sergio José Frangioni, CEO
投資者關係
Blanver首席執行官Sergio José Frangioni
Media
媒體
Herbert Silva: Herbert.silva@blanver.com.br
Lilia Lima de Almeida: lilia.almeida@blanver.com.br
Herbert Silva:Herbert.silva@blanver.com.br
Lilia Lima de Almeida:lilia.almeida@blanver.com.br
SOURCE: Biophytis
來源:Biophytis